FTC in­ves­ti­gates J&J con­tracts re­gard­ing the drug­mak­er's block­buster Rem­i­cade

In Sep­tem­ber 2017, Pfiz­er filed a law­suit al­leg­ing that J&J was col­lud­ing with in­sur­ers to en­sure the com­pa­ny’s block­buster au­toim­mune dis­ease drug, Rem­i­cade, was giv­en first pref­er­ence over its cheap­er biosim­i­lar. On Mon­day, J&J dis­closed that the US Fed­er­al Trade Com­mis­sion (FTC) was in­ves­ti­gat­ing whether the com­pa­ny had vi­o­lat­ed an­titrust laws, in a reg­u­la­to­ry fil­ing.

J&J’s Rem­i­cade, first ap­proved in 1998, is a bi­o­log­ic used to treat var­i­ous ail­ments in­clud­ing rheuma­toid arthri­tis, plaque pso­ri­a­sis, Crohn’s dis­ease and ul­cer­a­tive col­i­tis. In the sec­ond quar­ter, the Band-Aid mak­er gen­er­at­ed $1.12 bil­lion in glob­al Rem­i­cade sales.

Pfiz­er’s In­flec­tra is a biosim­i­lar ver­sion of Rem­i­cade and was grant­ed US ap­proval in 2016.

Un­like gener­ics — which can be read­i­ly sub­sti­tut­ed for brand­ed med­i­cines — biosim­i­lars are not ex­act copies of ex­pen­sive bi­o­log­ics, which are made from liv­ing cells, and are there­fore not in­ter­change­able (un­less they are cat­e­go­rized as such by the FDA). In the Unit­ed States, biosim­i­lars have seen mod­est up­take, in part due to the small­er mag­ni­tude of dif­fer­ence in list price be­tween the brand­ed bi­o­log­ic and biosim­i­lar.

In its law­suit in 2017, Pfiz­er said that J&J threat­ened to with­hold sig­nif­i­cant re­bates un­less in­sur­ers agreed to con­tracts that ef­fec­tive­ly thwart­ed cov­er­age for In­flec­tra and oth­er Rem­i­cade biosim­i­lars.

These ex­clu­sion­ary con­tracts have pushed in­sur­ers to not cov­er “In­flec­tra even though the Pfiz­er biosim­i­lar is avail­able at a Whole­sale Ac­qui­si­tion Cost that is 19 per­cent low­er than that of Rem­i­cade, and has an Av­er­age Sell­ing Price (ASP) that is more than 10 per­cent low­er,” Pfiz­er said in a state­ment.

J&J on Mon­day said the FTC had is­sued a “civ­il in­ves­tiga­tive de­mand” — which is on par with a  sub­poe­na — to de­ter­mine if its con­tract­ing prac­tices were le­gal.

End­points News has con­tact­ed Pfiz­er for com­ment.

So­cial im­age: Shut­ter­stock

Jeff Albers, Blueprint CEO

Di­ag­nos­tic champ Roche buys its way in­to the RET ti­tle fight with Eli Lil­ly, pay­ing $775M in cash to Blue­print

When Roche spelled out its original $1 billion deal — $45 million of that upfront — with Blueprint to discover targeted therapies against immunokinases, the biotech partner’s RET program was still preclinical. Four years later, pralsetinib is on the cusp of potential approval and the Swiss pharma giant is putting in much more to get in on the commercial game.

Roche gains rights to co-develop and co-commercialize the drug, with sole marketing responsibility for places outside the US and China (where CStone has staked its claim).

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,300+ biopharma pros reading Endpoints daily — and it's free.

Trans­port Sim­u­la­tion Test­ing for Your Ther­a­py is the Best Way to As­sure FDA Ex­pe­dit­ed Pro­gram Ap­proval

Modality Solutions is an ISO:9001-registered biopharmaceutical cold chain engineering firm with unique transport simulation capabilities that support accelerated regulatory approval for biologics and advanced therapeutic medicinal products (ATMP). Our expertise combines traditional validation engineering approaches with regulatory knowledge into a methodology tailored for the life sciences industry. We provide insight and execution for the challenges faced in your cold chain logistics network.

Source: Shutterstock

Who are the women blaz­ing trails in bio­phar­ma R&D and lead­ing the fight against Covid-19? Nom­i­nate them for End­points' spe­cial re­port

One of the many inequalities the pandemic has laid bare is the gender imbalance in biomedical research. A paper examining Covid-19 research authorship wondered out loud: Where are the women?

It’s a question that echoes beyond our current times. In the biopharma world, not only are women under-represented in R&D roles (particularly at higher levels), their achievements and talents could also be undermined by stereotypes and norms of leadership styles. The problem is even more dire for women of color.

Tal Zaks, Moderna CMO (Moderna via YouTube)

UP­DAT­ED: NI­AID and Mod­er­na spell out a 'ro­bust' im­mune re­sponse in PhI coro­n­avirus vac­cine test — but big ques­tions re­main to be an­swered

The NIAID and Moderna have spelled out positive Phase I safety and efficacy data for their Covid-19 vaccine mRNA-1273 — highlighting the first full, clear sketch of evidence that back-to-back jabs at the dose selected for Phase III routinely produced a swarm of antibodies to the virus that exceeded levels seen in convalescent patients — typically in multiples indicating a protective response.

Moderna execs say plainly that this first stage of research produced exactly the kind of efficacy they hoped to see in humans, with a manageable safety profile.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,300+ biopharma pros reading Endpoints daily — and it's free.

Mene Pangalos, AstraZeneca R&D chief (AstraZeneca via YouTube)

A day af­ter Mod­er­na vac­cine re­sults, ru­mors swirl of pend­ing As­traZeneca da­ta

A day after Moderna and the NIH published much-anticipated data from their Phase I Covid-19 vaccine trial, attention is turning to AstraZeneca which, according to a UK report, is expected to publish its own early data tomorrow.

ITV’s Robert Peston reported that AstraZeneca will publish the Phase I data in The Lancet. 

AstraZeneca and Moderna represent the two most ambitious Covid-19 vaccine efforts, having set the quickest timelines for approval (though they were recently joined in that regard by the Pfizer-BioNTech partnership) and some of the loftiest goals in total doses. Yet there is even less known about AstraZeneca’s vaccine’s effect on humans than there was about Moderna’s before yesterday. Although, in a controversial move, Moderna released some statistics from its Phase I in May, AstraZeneca has yet to say anything about what it saw in its Phase I trial — a move consistent with the scientific convention to withhold data until it can be published in a peer-reviewed journal.

Stéphane Bancel, Moderna CEO (Steven Ferdman/Getty Images)

‘Plan­ning to vac­ci­nate every­one in the US,’ Mod­er­na out­lines ef­forts to sup­ply their Covid-19 vac­cine as man­u­fac­tur­ing ramps up ahead of PhI­II

Twelve days from the planned start of their Phase III pivotal trial, the executive crew at Moderna has set up the manufacturing base needed to begin production of the first 500,000 doses of their Covid-19 vaccine with plans to feed it into a global supply chain. But the initial batches will likely be ready in the US first, where company CEO Stéphane Bancel plans to be able to vaccinate everyone.

“We have started making commercial product at-risk, and will continue to do so every day and every week of the month,” Bancel told analysts during their morning call on the Phase I data just published in the New England Journal of Medicine.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,300+ biopharma pros reading Endpoints daily — and it's free.

FDA rais­es ques­tions about Mallinck­rodt's HRS-1 drug be­fore ad­vi­so­ry hear­ing

Last August, UK drugmaker Mallinckrodt presented positive topline findings for its embattled terlipressin, illustrating the candidate met its primary endpoint in treating a life-threatening form of liver disease that causes kidney failure.

But the FDA continues to have questions about terlipressin’s safety and efficacy. After determining from the outset of the trial that the primary endpoint would only classify as a surrogate endpoint, the agency is questioning whether or not patients “trended toward clinical improvements” while on terlipressin. Regulators will convene in a hearing today and have released a document outlining their thinking ahead of the meeting.

FDA Ad­Com rec­om­mends GSK’s an­ti-BC­MA drug for ap­proval 12-0 de­spite sear­ing in-house re­view — does it mat­ter?

The FDA may have ripped GlaxoSmithKline for the safety of its anti-BCMA drug, but that didn’t stop an advisory committee from voting 12-0 to recommend approval for the multiple myeloma treatment.

The decision is in line with the committee’s long-running preference to approve cancer drugs that show enough efficacy and not overwhelming safety concerns, with the goal of giving oncologists as many tools to work with as possible as they treat individual patients. Yet while it signaled a strong likelihood of FDA approval — and boosted GSK’s stock by a nifty 1.6% — the vote still leaves open the question of how useful the drug will ultimately be and, accordingly, how well it will sell for a company trying to claw back into the cancer therapeutics business.

Covid-19 roundup: Vac­cine by end of 2020? Ken Fra­zier warns hype do­ing 'grave dis­ser­vice'

When it comes to setting expectations about a Covid-19 vaccine, Ken Frazier does not mince words.

Over a month after first casting doubts on the aggressive 12- to 18-month timeframe championed by the US government and his biopharma peers, the Merck CEO again cautioned against any hype around a quick vaccine approval.

In a wide-ranging interview with Harvard Business School professor Tsedal Neeley that touched other big topics such as race, Frazier emphasized that vaccines take a long time to develop. He would know: Out of the seven new vaccines introduced around the world in the past 25 years, four came from Merck.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,300+ biopharma pros reading Endpoints daily — and it's free.